Literature DB >> 20187510

Malignant fibrous histiocytoma: a case report and literature review.

Maroun Abou-Jaoude1, Mohamed El Ali.   

Abstract

Malignant fibrous histiocytoma (MFH) is the most common soft tissue sarcoma in late adult life. It occurs most frequently in the extremities (70%), followed by the retroperitoneum (16%). The occurrence of MFH in the spermatic cord is extremely rare (approximately 50 cases in the literature). We are reporting one case of MFH of the spermatic cord that presented as a hard painful inguinal mass. The patient was treated by a right radical orchiectomy followed by postoperative radiotherapy. The patient remained alive, with no local recurrence after 30 months of follow-up.

Entities:  

Mesh:

Year:  2009        PMID: 20187510

Source DB:  PubMed          Journal:  Int Surg        ISSN: 0020-8868


  4 in total

1.  Concurrence of malignant fibrohistiocytoma and Takayasu arteritis: a case report.

Authors:  Jin-Feng Du; Jin-Wei Chen; Fen Li; Jing Tian; Xi Xie; Ni Mao
Journal:  Rheumatol Int       Date:  2011-10-04       Impact factor: 2.631

2.  Successful treatment of advanced malignant fibrous histiocytoma of the right forearm with apatinib: a case report.

Authors:  Guanghui Ji; Liu Hong; Ping Yang
Journal:  Onco Targets Ther       Date:  2016-02-05       Impact factor: 4.147

Review 3.  Neoplastic diseases of the spermatic cord: an overview of pathological features, evaluation, and management.

Authors:  Gautam Dagur; Jason Gandhi; Kailash Kapadia; Rafid Inam; Noel L Smith; Gargi Joshi; Sardar Ali Khan
Journal:  Transl Androl Urol       Date:  2017-02

Review 4.  Cutaneous soft tissue sarcomas: survival-related factors.

Authors:  Areti Gkantaifi; Alexandros Diamantis; Davide Mauri; Ioanna Nixon; Anastassios Kyriazoglou; Ioannis Baloyiannis; Nikolaos Tsoukalas; Nikolaos Charalampakis; Dimitrios Schizas; Francesco Cuccia; Filippo Alongi; Ramon Andrade de Mello; George Iliadis; Konstantinos Kamposioras; Michalis Mazonakis; Maria Tolia
Journal:  Arch Dermatol Res       Date:  2021-07-17       Impact factor: 3.033

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.